NEW YORK (
(AGN - Get Report) was downgraded to at Deutsche Bank to hold and given a new price target of $98. Allergan's risk profile and future earnings estimates suffered as the FDA announced a nonclinical study pathway for generics to produce Restasis, AGN's second largest drug, Deutsche said.
Allergan was downgraded at Leerink Swann. Future earnings estimates have been lowered as concern mounts over generic production of the firm's second largest drug, said Leerink Swann. New market perform rating, price target $102.
(AMD - Get Report) was upgraded at FBR Capital Markets to outperform from market perform. $5.50 price target. Business appears to have stabilized for now, FBR Capital Markets said.
was upgraded to buy at Goldman Sachs. $47 price target. Company is leveraged to an increase in volatility, Goldman said.
was upgraded at Goldman Sachs to neutral from sell. Valuation call, based on a $70 price target, Goldman said.
was downgraded at Goldman Sachs to neutral from buy. Estimates were also cut, as the company is buying back fewer shares, Goldman Sachs said.
was downgraded at J.P.Morgan to underweight from neutral. U.S. crop fundamentals have passed their peak, J.P. Morgan said.
Digital Realty Trust
(DLR - Get Report)
was upgraded at UBS to neutral from sell. The risk/reward is balanced at current levels, UBS said.
was upgraded at Citigroup to neutral from sell. There's an expectation for a pickup in U.S.-centric flows, said Citigroup.
was initiated with an overweight rating at J.P. Morgan. $64 price target. Company should benefit from industry consolidation, J.P. Morgan said.
was upgraded at Goldman Sachs to neutral from sell. $68 price target. Company has solid margins and can exceed earnings expectations, Goldman Sachs said.
was downgraded to hold at TheStreet Ratings.
was downgraded at Wells Fargo to underperform from market perform. Company is losing its pricing power, Wells Fargo said.
was downgraded at Goldman Sachs. Valuation call, based on a $69 price target, Goldman said.
was downgraded at Wells Fargo to market perform from outperform. Industry competition is rising, Wells Fargo said.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts